TCI Wealth Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

TCI Wealth Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,680	Closed	-$5K	–	2495
2022 Q3	$5K	Buy	+2,680	New	+$7.51K	﹤0.01%	1412
2021 Q4	–	Sell	-619	Closed	-$3K	–	2291
2021 Q3	$3K	Buy	+619	New	+$3.12K	﹤0.01%	1893
2018 Q4	–	Sell	-59	Closed	-$1K	–	1430
2018 Q3	$1K	Hold	59	–	–	﹤0.01%	1147
2018 Q2	$1K	Buy	+59	New	+$1.03K	﹤0.01%	1230

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCI Wealth Advisors's AMRX Position: Q4 2022 in Review

TCI Wealth Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q4 2022, closing a stake of 2,680 shares — an estimated $5K sold.

TCI Wealth Advisors first reported a position in AMRX in Q2 2018 and held it in 4 quarters. The position peaked at $5K in Q3 2022. 156 funds tracked by Wall St. Rank hold AMRX as of Q4 2022.

TCI Wealth Advisors reported no remaining Amneal Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
TCI Wealth Advisors sold 2,680 Amneal Pharmaceuticals shares in Q4 2022, an estimated $5K.
TCI Wealth Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 4 quarters.
TCI Wealth Advisors's Amneal Pharmaceuticals position peaked at $5K in Q3 2022.
156 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2022.

Based on TCI Wealth Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.